Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
University of Maryland, Baltimore · Janssen (Belgium) · +11 more institutions
Abstract
The Ad26.COV2.S vaccine was highly effective against severe-critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis.
viral particles) or placebo. The primary end points were vaccine efficacy against moderate to severe-critical Covid-19 with onset at least 14 days after administration and at least 28 days after administration in the per-protocol population. Safety and key secondary and exploratory end points were also assessed.
Citation impact
- FWCI
- 24.60
- Percentile
- 100%
- References
- 23
Authors
29- JSJerald SadoffCorresponding
University of Maryland, Baltimore, Janssen (Belgium), Janssen (Netherlands)
- GGGlenda Gray
South African Medical Research Council, University of Maryland, Baltimore, Janssen (Belgium)
- AVAn Vandebosch
University of Maryland, Baltimore, Janssen (Belgium)
- VCVicky Cárdenas
University of Maryland, Baltimore, Janssen (Belgium), Janssen (United States)
- GSGeorgi Shukarev
University of Maryland, Baltimore, Janssen (Belgium), Janssen (Netherlands)
Topics & keywords
- Medicine
- Clinical efficacy
- Coronavirus disease 2019 (COVID-19)
- Disease
- Internal medicine
- Infectious disease (medical specialty)
- Good health and well-being